HEALTH PROFESSIONAL · SOURCE READING

HER2-targeted therapy (for patients with HER2 variants)

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Progressive Stage IV, Relapsed, and Recurrent NSCLC / Treatment Options for Progressive Stage IV, Relapsed, and Recurrent NSCLC (Second-Line Therapy)

Variants in the HER2 gene are found in 1% to 4% of patients with nonsquamous NSCLC. These HER2 variants are associated with female sex, Asian ethnicity, never-smoking status, a higher incidence of brain metastasis, moderate to poorly differentiated adenocarcinoma histology, and poor prognosis.[60,61]

Source links and citations

Continue within this section

Trastuzumab deruxtecan →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice